ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Celgene and BeiGene join for cancer drug

by Michael McCoy
July 10, 2017 | APPEARED IN VOLUME 95, ISSUE 28

Celgene and BeiGene will jointly develop BeiGene’s investigational anti-programmed cell death protein 1 inhibitor, BGB-A317, in the U.S., Europe, Japan, and the rest of the world outside Asia, where BeiGene will retain rights. BGB-A317 is an antibody that treats solid tumors. Celgene will pay BeiGene a $263 million license fee and acquire a 5.9% stake in the Chinese firm. BeiGene will acquire Celgene’s operations in China and gain a license to commercialize Celgene’s approved therapies in China.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment